Predictive Factors for the Prognosis of Vogt-Koyanagi-Harada Disease

References

• Rubsamen PE, Gass JE. Vogt–Koyanagi–Harada syndrome. Clinical course, therapy and long-term visual outcome. Arch Ophthalmol. 1991;109(5):682–687. doi:10.1001/archopht.1991.01080050096037.
   PubMedGoogle Scholar
• Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol. 1995;39(4):265–292. doi:10.1016/S0039-6257(05)80105-5.
   PubMed Web of Science ®Google Scholar
• Fang W, Yang P. Vogt-Koyanagi-Harada syndrome. Curr Eye Res. 33(7):517–523. doi:10.1080/02713680802233968.
   PubMed Web of Science ®Google Scholar
• Standardization of Uveitis Nomenclature (SUN) Working Group. Classification criteria for Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2021;228:205–211. doi:10.1016/j.ajo.2021.03.036.
   PubMed Web of Science ®Google Scholar
• Yang P, Ren Y, Li B, Fang, W, Meng Q, Kijlstra A. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology. 2007;114(3):606–614. doi:10.1016/j.ophtha.2006.07.040.
   PubMed Web of Science ®Google Scholar
• Herbort CP Jr, Abu El Asrar AM, Yamamoto JH, et al. Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality. Int Ophthalmol. 2017;37(6):1383–1395. doi:10.1007/s10792-016-0395-0.
   PubMed Web of Science ®Google Scholar
• Shen E, Rathinam SR, Babu M, et al. Outcomes of Vogt-Koyanagi-Harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. Am J Ophthalmol. 2016;168:279–286. doi:10.1016/j.ajo.2016.06.004.
   PubMed Web of Science ®Google Scholar
• Ohguro N, Sonoda KH, Takeuchi M, Matsumura M, Mochizuki M. The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. Jpn J Ophthalmol. 2012;56(5):432–435. doi:10.1007/s10384-012-0158-z.
   PubMed Web of Science ®Google Scholar
• Read RW, Rechodouni A, Butani N, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2001;131(5):599–606. doi:10.1016/S0002-9394(01)00937-0.
   PubMed Web of Science ®Google Scholar
• Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt–Koyanagi–Harada disease. Am J Ophthalmol. 2001;131(5):647–652. doi:10.1016/S0002-9394(01)00925-4.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492–513. doi:10.1016/S0002-9394(00)00659-0.
   PubMed Web of Science ®Google Scholar
• Al-Kharashi AS, Aldibhi H, Al-Fraykh H, Kangave D, Abu El-Asrar AM. Prognostic factors in Vogt–Koyanagi–Harada disease. Int Ophthalmol. 2007;27(2–3):201–210. doi:10.1007/s10792-007-9062-9.
   PubMedGoogle Scholar
• Chee SP, Jap A, Bacsal K. Prognostic factors of Vogt-Koyanagi-Harada disease in Singapore. Am J Ophthalmol. 2009;147(1):154–161. doi:10.1016/j.ajo.2008.07.044.
   PubMed Web of Science ®Google Scholar
• El-Asrar AM A, Al Tamimi M, Hemachandran S, Al-Mezaine HS, Al-Muammar A, Kangave D. Prognostic factors for clinical outcomes in patients with Vogt–Koyanagi–Harada disease treated with high-dose corticosteroids. Acta Ophthalmol. 2013;91(6):e486–493. doi:10.1111/aos.12127.
   PubMed Web of Science ®Google Scholar
• Okunuki Y, Tsubota K, Kezuka T, Goto H. Differences in the clinical features of two types of Vogt-Koyanagi-Harada disease: serous retinal detachment and optic disc swelling. Jpn J Ophthalmol. 2015;59(2):103–108. doi:10.1007/s10384-014-0367-8.
   PubMed Web of Science ®Google Scholar
• Ohno S, Char DH, Kimura SJ, O’Connor GR. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1977;83(5):735–740. doi:10.1016/0002-9394(77)90142-8.
   PubMed Web of Science ®Google Scholar
• Berker N, Ozdamar Y, Soykan E, Pinar O, Ozkan SS. Vogt-Koyanagi-Harada syndrome in children: report of a case and review of the literature. Ocul Immunol Inflamm. 2007;15(4):351–357. doi:10.1080/09273940701459453.
   PubMed Web of Science ®Google Scholar
• Tabbara KF, Chavis PS, Freeman WR. Vogt-Koyanagi-Harada syndrome in children compared to adults. Acta Ophthalmol Scand. 1998;76(6):723–726. doi:10.1034/j.1600-0420.1998.760619.x.
   PubMedGoogle Scholar
• Rathinam SR, Vijayalakshmi P, Namperumalsamy P, Nozik RA, Cunningham ET Jr. Vogt-Koyanagi-Harada syndrome in children. Ocul Immunol Inflamm. 1998;6(3):155–161. doi:10.1076/ocii.6.3.155.4041.
   PubMed Web of Science ®Google Scholar
• Sheu SJ, Kou HK, Chen JF. Significant prognostic factors for Vogt-Koyanagi-Harada disease in the early stage. Kaohsiung J Med Sci. 2004;20(3):97–105. doi:10.1016/S1607-551X(09)70092-0.
   PubMedGoogle Scholar
• Sakata VM, daSilva FT, Hirata CE, de Carvalho JF, Yamamoto JH. Diagnosis and classification of Vogt–Koyanagi–Harada disease. Autoimmun Rev. 2014;13(4–5):550–555. doi:10.1016/j.autrev.2014.01.023.
   PubMed Web of Science ®Google Scholar
• Urzua CA, Herbort C Jr, Valenzuela RA, et al. Initial-onset acute and chronic recurrent stages are two distinctive courses of Vogt-Koyanagi-Harada disease. J Ophthalmic Inflamm Infect. 2020;14;10(1):23. doi:10.1186/s12348-020-00214-2.
   PubMed Web of Science ®Google Scholar
• O’Keefe GA, Rao NA. Vogt-Koyanagi-Harada disease. Surv Ophthalmol. 2017;62(1):1–25. doi:10.1016/j.survophthal.2016.05.002.
   PubMed Web of Science ®Google Scholar
• Lavezzo MM, Sakata VM, Morita C, et al. Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes. Orphanet J Rare Dis. 2016;24(11):29. doi:10.1186/s13023-016-0412-4.
   Google Scholar
• Nakayama M, Keino H, Okada AA, et al. Enhanced depth imaging optical coherence tomography of the choroid in Vogt–Koyanagi–Harada disease. Retina. 2012;32(10):2061–2069. doi:10.1097/IAE.0b013e318256205a.
   PubMed Web of Science ®Google Scholar
• da Silva FT, Sakata VM, Nakashima A, et al. Enhanced depth imaging optical coherence tomography in long-standing Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2013;97(1):70–74. doi:10.1136/bjophthalmol-2012-302089.
   PubMed Web of Science ®Google Scholar
• Maleki A, Anesi SD, Look-Why S, Asgari S, Manhapra A, Foster CS. Clinical course and poor prognostic factors of Vogt-Koyanagi-Harada disease in a tertiary uveitis clinic. Can J Ophthalmol. 2022;57(2):142–144. doi:10.1016/j.jcjo.2021.04.005.
   PubMed Web of Science ®Google Scholar